Rades Dirk, Veninga Theo, Stalpers Lukas J A, Basic Hiba, Rudat Volker, Karstens Johann H, Dunst Juergen, Schild Steven E
Department of Radiation Oncology, University Hospital Schleswig-Holstein, Luebeck, Germany.
J Clin Oncol. 2007 Jan 1;25(1):50-6. doi: 10.1200/JCO.2006.08.7155.
To investigate outcome and prognosis of metastatic spinal cord compression (MSCC) patients with oligometastatic disease treated with radiotherapy alone.
Oligometastatic disease was defined as involvement of three or fewer vertebrae and lack of other bone or visceral metastases. Five hundred twenty-one patients with oligometastatic disease and MSCC were evaluated for functional outcome, ambulatory status, local control of MSCC, and survival. Furthermore, seven potential prognostic factors were investigated.
Motor function improved in 40% (n = 207), remained stable in 54% (n = 279), and deteriorated in 7% (n = 35) of patients. Fifty-eight (54%) of 107 nonambulatory patients became ambulatory, and 388 (94%) of 414 ambulatory patients remained ambulatory. Improved functional outcome was significantly associated with tumor type and slower development of motor deficits (> 14 days). Local control at 1, 2, and 3 years was 92%, 88%, and 78%, respectively. Improved local control was significantly associated with long-course radiotherapy. Survival at 1, 2, and 3 years was 71%, 58%, and 50%, respectively. Better survival was significantly associated with tumor type, ambulatory status, slower development of motor deficits, and long-course radiotherapy. Patients who developed motor deficits slowly (onset > 14 days before initiating treatment) were further analyzed. In this subgroup, the best results were observed for myeloma/lymphoma and breast cancer patients. No patient had progression of motor deficits. One hundred percent (myeloma/lymphoma) and 99% (breast cancer) of patients were ambulatory after radiotherapy. One-year local control was 100% and 98%, 1-year survival was 94% and 89%.
Given the limitations of a retrospective review, improved outcome of patients with oligometastatic MSCC was associated with myeloma/lymphoma and breast cancer, slower development of motor deficits, and a more prolonged course of radiation.
研究仅接受放疗的寡转移疾病转移性脊髓压迫(MSCC)患者的治疗结果和预后。
寡转移疾病定义为累及三个或更少椎体且无其他骨或内脏转移。对521例患有寡转移疾病和MSCC的患者进行了功能结局、行走状态、MSCC的局部控制和生存率评估。此外,还研究了七个潜在的预后因素。
40%(n = 207)的患者运动功能改善,54%(n = 279)的患者保持稳定,7%(n = 35)的患者运动功能恶化。107例不能行走的患者中有58例(54%)恢复行走,414例能行走的患者中有388例(94%)仍能行走。功能结局改善与肿瘤类型和运动功能障碍发展较慢(> 14天)显著相关。1年、2年和3年的局部控制率分别为92%、88%和78%。局部控制改善与长疗程放疗显著相关。1年、2年和3年的生存率分别为71%、58%和50%。更好的生存率与肿瘤类型、行走状态、运动功能障碍发展较慢和长疗程放疗显著相关。对运动功能障碍发展缓慢(开始治疗前发病> 14天)的患者进行了进一步分析。在这个亚组中,骨髓瘤/淋巴瘤和乳腺癌患者的结果最佳。没有患者出现运动功能障碍进展。放疗后,100%(骨髓瘤/淋巴瘤)和99%(乳腺癌)的患者能够行走。1年局部控制率为100%和98%,1年生存率为94%和89%。
鉴于回顾性研究的局限性,寡转移MSCC患者预后改善与骨髓瘤/淋巴瘤和乳腺癌、运动功能障碍发展较慢以及放疗疗程延长有关。